Latest Regulatory News

Rhythm Biosciences has successfully validated its ColoSTAT® colorectal cancer test, secured its first strategic partnership for Genetype, and secured $1 million in non-dilutive funding, setting the stage for a transformative FY26.

Neurotech International reports encouraging Phase I human pharmacokinetic results for its pediatric cannabinoid drug NTI164, alongside published clinical trial data in Rett Syndrome and key regulatory progress in the US and Australia.

Energy Resources of Australia Ltd narrowed its half-year loss to $35 million as it pressed ahead with the complex rehabilitation of the Ranger Project Area, backed by $1.24 billion in cash and investments. Meanwhile, Rio Tinto moves to compulsorily acquire remaining shares, signaling a new chapter for ERA’s future.

Po Valley Energy reports steady gas production from its Podere Maiar-1 field and progresses permitting for new wells in Italy, supported by robust cash reserves and ongoing stakeholder engagement.

Astron Corporation has cleared major regulatory hurdles for its Donald Rare Earth and Mineral Sands Project, releasing a robust updated economic study that underscores the project's long-term value and advancing financing discussions.

Acrux Limited has secured a decade-long licensing agreement with Servacure to commercialise its FDA-approved Dapsone 5% Gel in Saudi Arabia, marking a strategic step in its global expansion.

Helios Energy has made significant strides in transitioning from exploration to production at its Presidio Project in Texas, supported by a $2.6 million capital raise and strategic U.S. hires. Early oil recovery and positive engagement with partners underscore its growing momentum.

Titanium Sands Limited has secured retention licenses for four critical exploration areas and is progressing its Environmental Impact Assessment in Sri Lanka, while engaging government officials and local landowners to navigate regulatory hurdles.

Echelon Resources finalised its EP145 acquisition and reported a slight dip in production volumes, while Amadeus Basin receipts surged 24% thanks to new wells. The company maintains a strong cash position and is actively reshaping its portfolio for future growth.

Lithium Universe Limited has secured global rights to a breakthrough solar panel recycling technology that promises to unlock vast reserves of critical minerals, while advancing its Québec lithium refinery with robust financials and strategic partnerships.

Amplia Therapeutics reports encouraging ACCENT trial results for its FAK inhibitor narmafotinib, including rare complete responses in pancreatic cancer, alongside a $27.5 million capital raise to fund ongoing clinical development.

Silver Mines Limited progresses regulatory approvals for its flagship Bowdens Silver Project in NSW while acquiring promising US assets, enhancing its exploration pipeline with minimal upfront costs.